

**An Important Message from
The Texas Health and Human Services Commission (HHSC)**

**RSV Season and Synagis Prior Authorization Ends On Schedule
for All Health Service Regions**

Background:

Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and severe lung disease in infants and children. Synagis (palivizumab) is available for children with a high risk of infection.

Key Details:

VDP will end the 2025-26 respiratory syncytial virus season for all health service regions as scheduled. MCOs should no longer accept or review Synagis prior authorization requests once the region has closed.

MCO medical directors can end the RSV season for their MCO by service area if they demonstrate that local antigen positivity testing has dropped below 10% for two consecutive weeks, or that local PCR positivity has dropped below 3% for two consecutive weeks.

Resources:

[Respiratory Syncytial Virus Treatment](#)
[2025-26 RSV Season Schedule](#)

Questions?

For questions, please contact **UnitedHealthcare Customer Service at 888-887-9003, 8 a.m.–6 p.m. CT, Monday–Friday.**